The introduction of novel therapies, including BESREMi (PharmaEssentia/AOP Orphan Pharmaceuticals), INCB057643 (Incyte), XPOVIO (Karyopharm Therapeutics), RYTELO (Geron), REBLOZYL (Bristol Myers Squibb), Navtemadlin (Kartos Therapeutics), Pelabresib (Novartis), among others, is poised to reshape the myelofibrosis treatment landscape.
DelveInsight’s Myelofibrosis Market Insights report includes a comprehensive understanding of current treatment practices, emerging myelofibrosis drugs, market share of individual therapies, and current and forecasted myelofibrosis market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
Myelofibrosis Market Summary
- The total myelofibrosis treatment market across leading markets reached an estimated USD 2.2 billion in 2024. Among these, the United States represents the largest share of the market, outpacing the EU4, the UK, and Japan.
- According to DelveInsight’s 2024 analysis, the 7MM collectively reported approximately 56,000 prevalent myelofibrosis cases.
- Numerous leading companies, including PharmaEssentia, AOP Orphan Pharmaceuticals, Incyte, Karyopharm Therapeutics, Geron, Bristol Myers Squibb, Kartos Therapeutics, Novartis, Merck, Telios Pharma, Ryvu Therapeutics, Sumitomo Pharma, Syntara, Disc Medicine, Menarini Group, and others, are actively advancing innovative therapies for myelofibrosis.
- Several promising candidates in clinical development include BESREMi (ropeginterferon alfa-2b-njft/P-1101), INCB057643, XPOVIO (selinexor/KPT-330), RYTELO (imetelstat), REBLOZYL (luspatercept/ACE-536), Navtemadlin (KRT-232), Pelabresib (DAK539), Bomedemstat (IMG-7289/MK-3543), TL-895, RVU120 (SEL-120), TP-3654 (nuvisertib), SNT-5505 (PXS-5505), DISC-0974, and ELZONRIS (tagraxofusp/SL-401), among others. Many of these next-generation therapies are projected to enter the market during the forecast period and significantly reshape the treatment landscape.
- By 2034, OJJAARA/OMJJARA is expected to lead all therapies in terms of revenue.
Discover which myelofibrosis therapies are expected to grab the largest market share @ Myelofibrosis Market Report
What is Myelofibrosis?
Myelofibrosis is a rare form of blood cancer characterized by the buildup of scar tissue, known as fibrosis, in the bone marrow. This scarring disrupts the marrow’s ability to produce adequate healthy blood cells. The disease is part of a broader group of conditions called myeloproliferative neoplasms (MPNs), where bone marrow cells grow and function abnormally. When myelofibrosis develops on its own, without being triggered by a prior bone marrow disorder, it is called primary myelofibrosis. However, if it evolves from another MPN—such as polycythemia vera or essential thrombocythemia—it is classified as secondary myelofibrosis, often referred to as post-polycythemia vera or post-essential thrombocythemia myelofibrosis.
Myelofibrosis Epidemiology Segmentation
The myelofibrosis epidemiology section provides insights into the historical and current myelofibrosis patient pool and forecasted trends for the leading markets (the US, EU4, UK, and Japan). It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The myelofibrosis market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets (the US, EU4, UK, and Japan) segmented into:
- Total Prevalent Cases of Myelofibrosis
- Type-specific Cases of Myelofibrosis
- Myelofibrosis Cases Based on Risk Stratification
- Age-specific Prevalent Cases of Myelofibrosis
- Myelofibrosis Cases Based on Molecular Alterations
Download the report to understand which factors are driving myelofibrosis epidemiology trends @ Myelofibrosis Treatment Drugs
Myelofibrosis Market Analysis
JAK inhibitors have become a foundational therapy for myelofibrosis, providing substantial benefits such as reduced spleen volume, alleviation of disease-related symptoms, and improvements in overall quality of life, with evidence of extended survival in patients with advanced disease. While all approved JAK inhibitors primarily act on JAK2, especially the wild-type form, they vary in how they engage other members of the JAK family.
For example, JAKAFI for myelofibrosis blocks both JAK1 and JAK2; INREBIC is a selective JAK2 inhibitor that largely spares JAK1 but also targets FLT3 and additional pathways; VONJO inhibits JAK2 while sparing JAK1, with added effects on FLT3, IRAK, and ACVR1; and OJJAARA—approved via a distinct regulatory route—affects JAK1/JAK2 and ACVR1, particularly benefiting myelofibrosis patients with anemia. These mechanistic differences contribute to varied clinical outcomes.
Demand for JAKAFI in myelofibrosis remains robust and is projected to continue rising, reinforcing its role as the standard treatment. Myelofibrosis is expected to stay JAKAFI’s largest indication until polycythemia vera cases grow over time. However, future market expansion may be constrained by looming patent expirations, with JAKAFI protections ending in 2027 for Novartis and 2028 for Incyte, creating openings for competitors. In anticipation, Incyte is pursuing combination strategies with emerging agents to extend JAKAFI’s clinical relevance.
Learn more about the treatment options for myelofibrosis @ Myelofibrosis Therapy
Key Factors Driving the Growth of the Myelofibrosis Market
Novel Therapies Accelerate Progress in Myelofibrosis Treatment
Four JAK inhibitors, JAKAFI (ruxolitinib), INREBIC (fedratinib), VONJO (pacritinib), and OJJAARA (momelotinib), are currently approved by the US FDA for the treatment of myelofibrosis. While none offer a cure, they remain core therapies, particularly since most patients are older adults and therefore not candidates for stem cell transplantation. The introduction of another JAK inhibitor, BESREMi, is expected to further reshape the therapeutic landscape.
Expanding Pipeline and Rise of Non-JAK Mechanisms
A robust clinical pipeline is diversifying treatment options beyond JAK inhibition. Prominent approaches include BET inhibitors (Incyte’s INCB057643, Novartis’ Pelabresib), the XPO1 inhibitor XPOVIO (Karyopharm Therapeutics), telomerase inhibitor RYTELO (Geron), MDM2 inhibitor Navtemadlin (Kartos Therapeutics), tyrosine kinase inhibitor TL-895 (Telios Pharma), PIM1 inhibitor TP-3654 (Sumitomo Pharma), LOX inhibitor SNT-5505 (Syntara), among others. These candidates aim to deliver new indications, second-line choices, and potentially disease-modifying benefits—ultimately increasing the market’s long-term value.
Aging Demographics & Growing Disease Prevalence
Because myelofibrosis primarily impacts older adults, the aging global population is contributing to a rising patient base. Improved therapeutic management is also extending survival, further increasing prevalence. In the US in 2024, individuals aged 70 and above accounted for about 60% of all diagnosed cases, whereas those aged 39 or younger accounted for only about 2%.
Improved Diagnostics & Genomic Testing Expand the Patient Pool
Broader adoption of molecular testing, covering markers such as JAK2, CALR, and MPL, supports earlier detection, more precise diagnosis, and better treatment selection. These advancements are increasing the number of identified patients and enhancing alignment with targeted, higher-value therapies, boosting overall market growth.
Myelofibrosis Competitive Landscape
The myelofibrosis drug development pipeline features multiple mid- and late-stage candidates expected to reach the market within the forecast period. This expanding landscape includes a variety of emerging therapies, such as XPOVIO (Karyopharm Therapeutics), Elritercept (Takeda/Keros Therapeutics), Navtemadlin (Kartos Therapeutics), Pelabresib (Novartis), INCB057643 (Incyte), and Bomedemstat (Merck), positioned across different lines of treatment. Their anticipated approvals are likely to strengthen market growth further.
INCB057643 is an oral small-molecule inhibitor that targets BET proteins, key epigenetic regulators involved in oncogenic pathways linked to myelofibrosis and other blood cancers, including BCL-2, NF-κB, and c-Myc. Previous Phase I/II studies demonstrated good tolerability and encouraging activity when given alone or with ruxolitinib in advanced cancer patients. In its Q2 2025 update, the company confirmed that INCB057643, combined with ruxolitinib—and the dual JAK1/JAK2 and BET inhibitor INCB57643—is being assessed in an ongoing Phase II trial for myelofibrosis.
RYTELO (imetelstat) is a telomerase inhibitor designed to selectively eliminate malignant stem and progenitor cells responsible for diseases such as myelodysplastic syndromes and myelofibrosis. By suppressing these abnormal cells, imetelstat enables the restoration of healthy bone marrow function. Phase III data have demonstrated meaningful clinical benefits and disease-modifying activity. As of January 2025, Geron reported 75% enrollment in the Phase III IMpactMF trial comparing imetelstat with Best Available Therapy in patients with intermediate-2 or high-risk myelofibrosis who have relapsed or are refractory to JAK inhibitors.
Elritercept is a late-stage investigational activin pathway inhibitor intended to address anemia in hematologic malignancies, including myelofibrosis and MDS. It is currently under Phase II investigation for myelofibrosis. Updated clinical data were presented at ASH 2024. In December 2024, Takeda entered an exclusive global licensing agreement (excluding mainland China, Hong Kong, and Macau) with Keros to advance its development and commercialization.
Collectively, these innovative therapies are expected to redefine the therapeutic landscape for myelofibrosis over the next several years. As they progress through clinical development and move toward regulatory approval, they are poised to set new treatment benchmarks and fuel further innovation and market expansion.
To know more about new myelofibrosis treatment, visit @ Myelofibrosis Treatment Market
Recent Developments in the Myelofibrosis Market
- In July 2025, Incyte announced that the Phase I data in patients with myelofibrosis as monotherapy and in combination with ruxolitinib are anticipated in the second half of 2025.
- In June 2025, QIAGEN and Incyte announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), including Incyte’s monoclonal antibody INCA033989.
- In January 2025, Karyopharm Therapeutics stated that it expects to report top-line results from the Phase III SENTRY trial in the second half of 2025, which could represent a potentially transformative opportunity to establish a new treatment paradigm in myelofibrosis.
| Myelofibrosis Market Report Metrics | Details |
| Study Period | 2020–2034 |
| Myelofibrosis Market Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Myelofibrosis Market CAGR | 9% |
| Myelofibrosis Market Size in 2024 | USD 2.2 Billion |
| Key Myelofibrosis Companies | PharmaEssentia, AOP Orphan Pharmaceuticals, Incyte, Karyopharm Therapeutics, Geron, Bristol Myers Squibb, Kartos Therapeutics, Novartis, Merck, Telios Pharma, Ryvu Therapeutics, Sumitomo Pharma, Syntara, Disc Medicine, Menarini Group, and others |
| Key Myelofibrosis Therapies | BESREMi (ropeginterferon alfa-2b-njft/P-1101), INCB057643, XPOVIO (NEXPOVIO/selinexor/KPT-330), RYTELO (imetelstat), REBLOZYL (luspatercept/ACE-536), Navtemadlin (KRT-232), Pelabresib (DAK539), Bomedemstat (IMG-7289/MK-3543), TL-895, RVU120 ( SEL-120), TP-3654 (nuvisertib), SNT-5505 (PXS-5505), DISC-0974, ELZONRIS (tagraxofusp/SL-401), and others |
Scope of the Myelofibrosis Market Report
- Myelofibrosis Therapeutic Assessment: Myelofibrosis current marketed and emerging therapies
- Myelofibrosis Market Dynamics: Conjoint Analysis of Emerging Myelofibrosis Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Myelofibrosis Market Unmet Needs, KOL’s views, Analyst’s views, Myelofibrosis Market Access and Reimbursement
Discover more about myelofibrosis drugs in development @ Myelofibrosis Clinical Trials
Table of Contents
| 1 | MYELOFIBROSIS MARKET KEY INSIGHTS |
| 2 | MYELOFIBROSIS MARKET REPORT INTRODUCTION |
| 3 | EXECUTIVE SUMMARY OF MYELOFIBROSIS |
| 4 | MYELOFIBROSIS EPIDEMIOLOGY AND MARKET METHODOLOGY |
| 5 | KEY EVENTS |
| 6 | MYELOFIBROSIS MARKET OVERVIEW AT A GLANCE |
| 6.1 | MARKET SHARE (%) DISTRIBUTION OF MYELOFIBROSIS BY THERAPIES IN 2024 |
| 6.2 | MARKET SHARE (%) DISTRIBUTION OF MYELOFIBROSIS BY THERAPIES IN 2034 |
| 7 | DISEASE BACKGROUND AND OVERVIEW |
| 7.1 | INTRODUCTION |
| 7.2 | MYELOFIBROSIS SUBTYPES |
| 7.3 | MYELOFIBROSIS SIGNS AND SYMPTOMS |
| 7.4 | MYELOFIBROSIS CAUSES |
| 7.5 | MYELOFIBROSIS PATHOGENESIS |
| 7.6 | MYELOFIBROSIS PROGNOSIS |
| 7.7 | MYELOFIBROSIS RISK FACTOR |
| 7.8 | MYELOFIBROSIS DIAGNOSIS |
| 8 | MYELOFIBROSIS TREATMENT AND MANAGEMENT |
| 9 | MYELOFIBROSIS GUIDELINES |
| 9.1 | NCCN GUIDELINES |
| 9.2 | NICE GUIDELINES |
| 9.3 | ESMO GUIDELINES (POST PV AND POST ET) |
| 9.4 | THE MANAGEMENT OF MYELOFIBROSIS: A BRITISH SOCIETY FOR HEMATOLOGY GUIDELINE |
| 10 | MYELOFIBROSIS EPIDEMIOLOGY AND PATIENT POPULATION |
| 10.1 | KEY FINDINGS |
| 10.2 | ASSUMPTIONS AND RATIONALE |
| 10.3 | TOTAL PREVALENT CASES OF MYELOFIBROSIS IN THE 7MM |
| 10.4 | THE UNITED STATES |
| 10.4.1 | Total Prevalent Cases of Myelofibrosis in the United States |
| 10.4.2 | Type-specific Cases of Myelofibrosis in the United States |
| 10.4.3 | Myelofibrosis Cases Based on Risk Stratification in the United States |
| 10.4.4 | Age-specific Cases of Myelofibrosis in the United States |
| 10.4.5 | Myelofibrosis Cases Based on Molecular Alterations in the United States |
| 10.5 | EU4 AND THE UK |
| 10.6 | JAPAN |
| 11 | MYELOFIBROSIS PATIENT JOURNEY |
| 11.1 | DESCRIPTION |
| 12 | KEY ENDPOINTS IN MYELOFIBROSIS CLINICAL TRIALS |
| 13 | MARKETED MYELOFIBROSIS DRUGS |
| 13.1 | KEY COMPETITORS |
| 13.2 | MYELOFIBROSIS JAKAFI/JAKAVI (RUXOLITINIB): INCYTE/NOVARTIS |
| 13.2.1 | Product Description |
| 13.2.2 | Regulatory Milestones |
| 13.2.3 | Other Developmental Activities |
| 13.2.4 | Clinical Development |
| 13.2.5 | Safety and Efficacy |
| 13.2.6 | Product Profile |
| 13.3 | INREBIC (FEDRATINIB): BRISTOL MYERS SQUIBB |
| 13.4 | VONJO MYELOFIBROSIS: SWEDISH ORPHAN BIOVITRUM/CTI BIOPHARMA |
| 13.5 | OJJAARA/OMJJARA (MOMELOTINIB MYELOFIBROSIS): GSK/SIERRA ONCOLOGY |
| 14 | EMERGING MYELOFIBROSIS THERAPIES |
| 14.1 | KEY COMPETITORS |
| 14.2 | PELABRESIB: MORPHOSYS |
| 14.2.1 | Product Description |
| 14.2.2 | Other Developmental Activities |
| 14.2.3 | Clinical Development |
| 14.2.4 | Safety and Efficacy |
| 14.3 | IMETELSTAT: GERON |
| 14.4 | REBLOZYL (LUSPATERCEPT/ACE-536): BRISTOL MYERS SQUIBB |
| 14.5 | NAVTEMADLIN (KRT-232): KARTOS THERAPEUTICS |
| Further details in the report… | |
| 15 | MYELOFIBROSIS MARKET: 7 MAJOR MARKET ANALYSIS |
| 15.1 | KEY FINDINGS |
| 15.2 | MYELOFIBROSIS MARKET OUTLOOK |
| 15.3 | CONJOINT ANALYSIS |
| 15.4 | KEY MYELOFIBROSIS MARKET FORECAST ASSUMPTIONS |
| 15.5 | TOTAL MARKET SIZE OF MYELOFIBROSIS IN THE 7MM |
| 15.6 | UNITED STATES MYELOFIBROSIS MARKET SIZE |
| 15.6.1 | Total Market Size of Myelofibrosis in the United States |
| 15.6.2 | Market Size of Myelofibrosis by Therapies in the United States |
| 15.1 | EU4 AND THE UK MYELOFIBROSIS MARKET SIZE |
| 15.2 | JAPAN MYELOFIBROSIS MARKET SIZE |
| 16 | MYELOFIBROSIS MARKET ACCESS AND REIMBURSEMENT |
| 16.1 | UNITED STATES |
| 16.2 | EU4 AND THE UK |
| 16.3 | JAPAN |
| 16.4 | MYELOFIBROSIS MARKET ACCESS AND REIMBURSEMENT |
| 16.4.1 | United States |
| 16.4.2 | NICE UK |
| 16.4.3 | HAS France |
| 16.4.4 | The Agence nationale de sécurité du médicament et des produits de santé (ANSM) |
| 16.4.5 | IQWIG Germany |
| 16.4.6 | The Federal Institute for Drugs and Medical Devices (BfArM) |
| 16.4.7 | AIFA Italy |
| 16.4.8 | MHLW Japan |
| 17 | MYELOFIBROSIS MARKET SWOT ANALYSIS |
| 18 | MYELOFIBROSIS MARKET UNMET NEEDS |
| 19 | KOL VIEWS ON MYELOFIBROSIS |
| 20 | BIBLIOGRAPHY |
| 21 | MYELOFIBROSIS MARKET REPORT METHODOLOGY |
Related Reports
JAK Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key JAK inhibitors companies, including Pfizer, AbbVie, Galapagos, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, among others.
Myelofibrosis Clinical Trial Analysis
Myelofibrosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myelofibrosis companies, including Geron Corporation, Merck, Ryvu Therapeutics SA, Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, Sumitomo Pharma America, Inc., Cellenkos, Disc Medicine, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
